EE04354B1 - Indolüül-3-glüoksüülhappe derivaadid, nende kasutamine ravimite valmistamiseks ja neid sisaldavad kasvajavastase toimega ravimid - Google Patents

Indolüül-3-glüoksüülhappe derivaadid, nende kasutamine ravimite valmistamiseks ja neid sisaldavad kasvajavastase toimega ravimid

Info

Publication number
EE04354B1
EE04354B1 EEP200000581A EEP200000581A EE04354B1 EE 04354 B1 EE04354 B1 EE 04354B1 EE P200000581 A EEP200000581 A EE P200000581A EE P200000581 A EEP200000581 A EE P200000581A EE 04354 B1 EE04354 B1 EE 04354B1
Authority
EE
Estonia
Prior art keywords
medicaments
indolyl
manufacture
acid derivatives
glyoxylic acid
Prior art date
Application number
EEP200000581A
Other languages
English (en)
Estonian (et)
Inventor
Nickel Bernd
Szelenyi Istvan
Schmidt Jrgen
Emig Peter
Reichert Dietmar
G�Nther Eckhard
Brune Kay
Original Assignee
Asta Medica Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Aktiengesellschaft filed Critical Asta Medica Aktiengesellschaft
Publication of EE200000581A publication Critical patent/EE200000581A/xx
Publication of EE04354B1 publication Critical patent/EE04354B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
EEP200000581A 1998-04-02 1999-03-22 Indolüül-3-glüoksüülhappe derivaadid, nende kasutamine ravimite valmistamiseks ja neid sisaldavad kasvajavastase toimega ravimid EE04354B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814838A DE19814838C2 (de) 1998-04-02 1998-04-02 Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
PCT/EP1999/001918 WO1999051224A1 (de) 1998-04-02 1999-03-22 Indolyl-3-glyoxylsäure-derivate mit antitumorwirkung

Publications (2)

Publication Number Publication Date
EE200000581A EE200000581A (et) 2002-02-15
EE04354B1 true EE04354B1 (et) 2004-10-15

Family

ID=7863398

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000581A EE04354B1 (et) 1998-04-02 1999-03-22 Indolüül-3-glüoksüülhappe derivaadid, nende kasutamine ravimite valmistamiseks ja neid sisaldavad kasvajavastase toimega ravimid

Country Status (33)

Country Link
US (4) US6232327B1 (da)
EP (1) EP1071420B1 (da)
JP (2) JP5253696B2 (da)
KR (1) KR100583545B1 (da)
CN (1) CN1148183C (da)
AR (1) AR018175A1 (da)
AT (1) ATE304352T1 (da)
AU (1) AU768510B2 (da)
BG (1) BG64838B1 (da)
BR (1) BR9909902A (da)
CA (1) CA2326833C (da)
DE (2) DE19814838C2 (da)
DK (1) DK1071420T3 (da)
EE (1) EE04354B1 (da)
ES (1) ES2249884T3 (da)
GE (1) GEP20032967B (da)
HK (1) HK1036408A1 (da)
HR (1) HRP20000643A2 (da)
HU (1) HUP0101530A3 (da)
ID (1) ID26504A (da)
IL (2) IL138737A0 (da)
IS (1) IS2307B (da)
NO (1) NO327721B1 (da)
NZ (1) NZ507084A (da)
PL (1) PL192779B1 (da)
RS (1) RS49866B (da)
RU (1) RU2262339C2 (da)
SK (1) SK286393B6 (da)
TR (1) TR200002853T2 (da)
TW (1) TWI230608B (da)
UA (1) UA70942C2 (da)
WO (1) WO1999051224A1 (da)
ZA (1) ZA200006150B (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19946301A1 (de) 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
AU4834200A (en) * 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
US6849656B1 (en) * 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
JP4187441B2 (ja) * 1999-09-17 2008-11-26 ベイラー・ユニバーシテイ インドール含有およびコンブレタスタチン関連の抗有糸分裂および抗チューブリン重合薬剤
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
CA2391952C (en) * 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
GB9928696D0 (en) 1999-12-03 2000-02-02 Swan Thomas & Co Ltd Optical devices and methods of manufacture thereof
IT1315267B1 (it) 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
IT1318641B1 (it) * 2000-07-25 2003-08-27 Novuspharma Spa Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
JP2005504790A (ja) * 2001-09-13 2005-02-17 シンタ ファーマスーティカルズ コーポレイション 癌を治療するための3−グリオキシリルアミドインドール
TWI323658B (en) 2001-12-06 2010-04-21 Nat Health Research Institutes Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
TWI324596B (en) 2002-08-26 2010-05-11 Nat Health Research Institutes Imidazolamino compounds
CN1726191A (zh) * 2002-12-10 2006-01-25 惠氏公司 用作纤溶酶原激活物抑制剂-1(pai-1)的抑制剂的取代的吲哚氧代-乙酰氨基乙酸衍生物
DE10318611A1 (de) 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect
EP1484329A1 (de) * 2003-06-06 2004-12-08 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
BRPI0410998A (pt) * 2003-06-05 2006-07-04 Zentaris Gmbh derivados de indol com efeito de indução de apoptose
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
MXPA06002853A (es) 2003-09-11 2006-06-14 Kemia Inc Inhibidores citoquina.
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
WO2006002887A1 (en) * 2004-06-29 2006-01-12 Baxter International Inc. Aqueous drink solution of indibulin (d-24851) and an organic acid
MX2007005434A (es) * 2004-11-08 2007-07-10 Baxter Int Composiciones de nanoparticulado de inhibidor de tubulina.
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP2363128B1 (en) * 2005-03-11 2016-02-17 Vertex Pharmaceuticals Incorporated Indole modulators of ATP-binding cassette transporters
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
JP2009511494A (ja) * 2005-10-06 2009-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド Atp結合カセットトランスポーターのモジュレーター
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
SG176477A1 (en) * 2006-08-07 2011-12-29 Ironwood Pharmaceuticals Inc Indole compounds
AU2007325797B2 (en) * 2006-11-28 2014-03-13 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
EP1964835A1 (en) * 2007-02-28 2008-09-03 Centre National de la Recherche Scientifique Derivatives of psammaplin A, a method for their synthesis and their use for the prevention or treatment of cancer
CN101085779A (zh) * 2007-07-11 2007-12-12 中国人民武装警察部队医学院 取代吲哚-3-基草酰表鬼臼毒素衍生物及其盐及其用途
GB0715103D0 (en) * 2007-08-03 2007-09-12 Lectus Therapeutics Ltd Calcium ion channel modulators and uses thereof
GB0909441D0 (en) * 2009-06-02 2009-07-15 Univ Sheffield Novel indole derivatives
US9585810B2 (en) 2010-10-14 2017-03-07 Fresenius Medical Care Holdings, Inc. Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
JP6208122B2 (ja) 2011-05-12 2017-10-04 プロテオステイシス セラピューティクス,インコーポレイテッド プロテオスタシス調節因子
EP2744803A2 (en) 2011-08-18 2014-06-25 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質(cetp)インヒビターとしての5−ベンジルアミノメチル−6−アミノピラゾロ[3,4−b]ピリジン誘導体
CN102942516B (zh) * 2012-11-05 2015-02-25 宁波大学 一种生物碱类化合物及其制备方法和应用
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
IL225540A (en) * 2013-04-02 2015-09-24 Igal Nir A method, system, and software for automatically generating a speech database for speech recognition
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
CN105198788A (zh) * 2015-09-30 2015-12-30 蒋军荣 一种吲哚氧代乙酰(n-二芳甲基)哌嗪衍生物及其制备方法和应用
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1028812A (en) * 1962-08-28 1966-05-11 Ici Ltd Indole derivatives
GB1089071A (en) * 1964-02-28 1967-11-01 Merck & Co Inc Indole derivatives
FR2182915A1 (en) * 1972-03-30 1973-12-14 Nelson Res & Dev Substd indoles, benzimidazoles - as anti-immune agents , antitumour agents, serotonin inhibitors, hypnotics
WO1994008581A1 (en) * 1992-10-20 1994-04-28 Toray Industries, Inc. Eosinophil infiltration inhibitor
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
PT675110E (pt) * 1994-04-01 2002-11-29 Lilly Co Eli 1h-indole-3-glioxilamidas inibidoras da spla2
ES2124064T3 (es) * 1995-06-07 1999-01-16 Lilly Co Eli Compuestos y composiciones con cadenas laterales nitrogenadas no basicas.
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
US6225329B1 (en) * 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
WO1999046237A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
EP1475377B1 (de) 1998-04-28 2006-06-21 elbion AG Indolderivate und deren Verwendung als Inhibitoren der Phosphodiesterase 4.
JP2000239252A (ja) 1999-02-16 2000-09-05 Mitsubishi Chemicals Corp インドール誘導体
AU4834200A (en) 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
US7205299B2 (en) 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect
DE102004031538A1 (de) 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
US20060280787A1 (en) 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof

Also Published As

Publication number Publication date
RS49866B (sr) 2008-08-07
ZA200006150B (en) 2001-01-11
AR018175A1 (es) 2001-10-31
HUP0101530A3 (en) 2002-12-28
EE200000581A (et) 2002-02-15
AU2934999A (en) 1999-10-25
US7579365B2 (en) 2009-08-25
IL138737A (en) 2007-02-11
DE19814838A1 (de) 1999-10-14
NO327721B1 (no) 2009-09-14
CA2326833A1 (en) 1999-10-14
US20030195360A1 (en) 2003-10-16
KR100583545B1 (ko) 2006-05-26
DE59912562D1 (en) 2005-10-20
EP1071420A1 (de) 2001-01-31
SK14302000A3 (sk) 2001-11-06
ES2249884T3 (es) 2006-04-01
IS2307B (is) 2007-10-15
US20030023093A1 (en) 2003-01-30
TR200002853T2 (tr) 2001-02-21
JP2002510622A (ja) 2002-04-09
BG64838B1 (bg) 2006-06-30
IL138737A0 (en) 2001-10-31
HUP0101530A2 (hu) 2001-11-28
KR20010042368A (ko) 2001-05-25
CN1299280A (zh) 2001-06-13
IS5635A (is) 2000-09-22
NO20004916D0 (no) 2000-09-29
SK286393B6 (sk) 2008-09-05
HRP20000643A2 (en) 2001-04-30
WO1999051224A1 (de) 1999-10-14
NO20004916L (no) 2000-12-01
TWI230608B (en) 2005-04-11
JP5253696B2 (ja) 2013-07-31
GEP20032967B (en) 2003-05-27
DE19814838C2 (de) 2001-01-18
EP1071420B1 (de) 2005-09-14
UA70942C2 (uk) 2004-11-15
US6232327B1 (en) 2001-05-15
BG104849A (en) 2001-05-31
YU59300A (sh) 2002-11-15
ID26504A (id) 2001-01-11
NZ507084A (en) 2003-10-31
CN1148183C (zh) 2004-05-05
PL343525A1 (en) 2001-08-27
PL192779B1 (pl) 2006-12-29
JP2011148809A (ja) 2011-08-04
AU768510B2 (en) 2003-12-18
ATE304352T1 (de) 2005-09-15
US20080027110A1 (en) 2008-01-31
DK1071420T3 (da) 2006-01-16
RU2262339C2 (ru) 2005-10-20
HK1036408A1 (en) 2002-01-04
CA2326833C (en) 2009-06-23
BR9909902A (pt) 2000-12-26

Similar Documents

Publication Publication Date Title
EE04354B1 (et) Indolüül-3-glüoksüülhappe derivaadid, nende kasutamine ravimite valmistamiseks ja neid sisaldavad kasvajavastase toimega ravimid
EE200400059A (et) Diarüültsükloalküülderivaadid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
EE04273B1 (et) Bensotsüklohepteenid, nende valmistamise meetod, neid sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks
EE200000168A (et) Karboksamidotiasoolderivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
EE9700153A (et) Heterotsükliga kondenseerunud püridiinid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
EE9700060A (et) 2-arüül-asendatud püridiinid,nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
EE9700031A (et) Pürido-liitunud tienüül- ja furanüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
EE9800028A (et) Iprotroopiumsoolad, neid sisaldavad ravimkompositsioonid ja nende kasutamine
NO20011216L (no) Azetidinderivater, deres fremstilling og medikamenter inneholdende forbindelsene
EE04399B1 (et) Spiroasabitsüklilised heterotsüklilised ühendid, nende valmistamise protsess, neid sisaldavad ravimkoostised ja nende kasutamine ravis
EE9700145A (et) Tsükloalkaanpüridiinid, nende valmistamismeetod, kasutamine ravimite tootmiseks ja nimetatud ühendeid sisaldavad ravimid
EE200000037A (et) Atsüülpiperasinüülpürimidiinide derivaadid, nende valmistamine ja kasutamine ravimitena
HUP0104497A3 (en) Benzamide derivatives, their preparation, medicaments containing them and their use
EE9700020A (et) Heteroaatomit sisaldavad tsülopentaanpüridüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
EE200200138A (et) Kinolüülpropüülpiperidiini derivaadid, nende valmistamine ja neid sisaldavad kompositsioonid
EE9700044A (et) Heteroarüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid.
EE200100258A (et) Antraniilhappe amiidid ja nende kasutamine ravimitena
EE04236B1 (et) Bensimidasoolid, nende valmistamine ja kasutamineravimitena
EE9700019A (et) 2-okso- ja 2-tio1,2-dihüdrokinolinüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
DE59814449D1 (de) Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
EE200300110A (et) Kaneelhappe asendatud guanidiidid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav ravim
EE04853B1 (et) Adenosiini derivaadid ja neid sisaldavad farmatseutilised kompositsioonid kasutamiseks meditsiinis
EE200200041A (et) Karboksüülhappeamiidid, neid ühendeid sisaldavad ravimid, nende kasutamine ja valmistamine
HUP0102766A2 (hu) Aminometilkarbonsavszármazékok, gyógyászati alkalmazásuk és ilyen vegyületeket tartalmazó gyógyászati készítmények
LV12624A (lv) Thienylazolylalcoxyethanamines their preparation and their application as medicaments

Legal Events

Date Code Title Description
HK1A Erratum in gazette
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20150322